Literature DB >> 17065134

Valproic acid does not affect markers of human immunodeficiency virus disease progression.

Beau M Ances1, Scott Letendre, Maria Buzzell, Jennifer Marquie-Beck, Deborah Lazaretto, Thomas D Marcotte, Igor Grant, Ronald J Ellis.   

Abstract

Valproic acid (VPA) reduces latent human immunodeficiency virus (HIV) reservoirs by activating resting CD4+ cells. This retrospective case-control study (n = 30) examined effects of VPA on markers of HIV progression. VPA was not associated with changes in cerebrospinal fluid viral loads (VL), plasma VL, or neuropsychological performance. VPA patients had a trend towards lower CD4+ cells (P = .08) at follow-up. Concurrent antiretrovirals did not alter these relationships. VPA does not induce viremia or promote disease progression and may be safe for clinical intervention.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17065134     DOI： 10.1080/13550280600981695

Source DB:  PubMed          Journal:  J Neurovirol        ISSN： 1355-0284            Impact factor:   2.643


  8 in total

1.  Initial validation of a screening battery for the detection of HIV-associated cognitive impairment.

Authors:  Catherine L Carey; Steven Paul Woods; Julie D Rippeth; Raul Gonzalez; David J Moore; Thomas D Marcotte; Igor Grant; Robert K Heaton
Journal:  Clin Neuropsychol       Date:  2004-05       Impact factor: 3.535

2.  Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.

Authors:  Ginger Lehrman; Ian B Hogue; Sarah Palmer; Cheryl Jennings; Celsa A Spina; Ann Wiegand; Alan L Landay; Robert W Coombs; Douglas D Richman; John W Mellors; John M Coffin; Ronald J Bosch; David M Margolis
Journal:  Lancet       Date:  2005 Aug 13-19       Impact factor: 79.321

3.  Modulation of human immunodeficiency virus infection by anticonvulsant drugs.

Authors:  Barry Robinson; Jadwiga Turchan; Caroline Anderson; Ashok Chauhan; Avindra Nath
Journal:  J Neurovirol       Date:  2006-02       Impact factor: 2.643

Review 4.  Hematologic toxicity of sodium valproate.

Authors:  S Acharya; J B Bussel
Journal:  J Pediatr Hematol Oncol       Date:  2000 Jan-Feb       Impact factor: 1.289

5.  The impact of HIV-associated neuropsychological impairment on everyday functioning.

Authors:  Robert K Heaton; Thomas D Marcotte; Monica Rivera Mindt; Joseph Sadek; David J Moore; Heather Bentley; J Allen McCutchan; Carla Reicks; Igor Grant
Journal:  J Int Neuropsychol Soc       Date:  2004-05       Impact factor: 2.892

6.  Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report.

Authors:  G Schifitto; D R Peterson; J Zhong; H Ni; K Cruttenden; M Gaugh; H E Gendelman; M Boska; H Gelbard
Journal:  Neurology       Date:  2006-03-01       Impact factor: 9.910

7.  Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression.

Authors:  Loyda Ylisastigui; Nancie M Archin; Ginger Lehrman; Ronald J Bosch; David M Margolis
Journal:  AIDS       Date:  2004-05-21       Impact factor: 4.177

8.  Valproic acid and HIV-1 latency: beyond the sound bite.

Authors:  Stephen M Smith
Journal:  Retrovirology       Date:  2005-09-19       Impact factor: 4.602
  8 in total
  7 in total

1.  The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system.

Authors:  Scott L Letendre; Jennifer Marquie-Beck; Ronald J Ellis; Steven Paul Woods; Brookie Best; David B Clifford; Ann C Collier; Benjamin B Gelman; Christina Marra; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Terry J Alexander; Janis Durelle; Robert Heaton; Igor Grant
Journal:  J Neuroimmune Pharmacol       Date:  2007-01-03       Impact factor: 4.147

Review 2.  HIV-associated neurocognitive disorder.

Authors:  David B Clifford; Beau M Ances
Journal:  Lancet Infect Dis       Date:  2013-11       Impact factor: 25.071

3.  Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma.

Authors:  Leonard C Edelstein; Sophia Micheva-Viteva; Bradley D Phelan; Joseph P Dougherty
Journal:  AIDS Res Hum Retroviruses       Date:  2009-09       Impact factor: 2.205

Review 4.  Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS.

Authors:  Stephen Dewhurst; Sanjay B Maggirwar; Giovanni Schifitto; Howard E Gendelman; Harris A Gelbard
Journal:  J Neuroimmune Pharmacol       Date:  2006-12-16       Impact factor: 4.147

5.  Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS.

Authors:  Kathy Lee; Pornpun Vivithanaporn; Reed A Siemieniuk; Hartmut B Krentz; Ferdinand Maingat; M John Gill; Christopher Power
Journal:  BMC Neurol       Date:  2010-06-17       Impact factor: 2.474

6.  Valproic acid inhibits the release of soluble CD40L induced by non-nucleoside reverse transcriptase inhibitors in human immunodeficiency virus infected individuals.

Authors:  Donna C Davidson; Giovanni Schifitto; Sanjay B Maggirwar
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

Review 7.  Targeting platelet-derived soluble CD40 ligand: a new treatment strategy for HIV-associated neuroinflammation?

Authors:  Donna C Davidson; Joseph W Jackson; Sanjay B Maggirwar
Journal:  J Neuroinflammation       Date:  2013-12-01       Impact factor: 8.322
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.